ES2611852T3 - Donadores de nitroxilo para el tratamiento de la hipertensión pulmonar - Google Patents
Donadores de nitroxilo para el tratamiento de la hipertensión pulmonar Download PDFInfo
- Publication number
- ES2611852T3 ES2611852T3 ES10784416.9T ES10784416T ES2611852T3 ES 2611852 T3 ES2611852 T3 ES 2611852T3 ES 10784416 T ES10784416 T ES 10784416T ES 2611852 T3 ES2611852 T3 ES 2611852T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- alkyl
- compound
- nitroxyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 title abstract description 34
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract description 21
- 150000001875 compounds Chemical class 0.000 abstract description 66
- 125000000217 alkyl group Chemical group 0.000 abstract description 50
- -1 perhaloalkoxy Chemical group 0.000 abstract description 35
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract description 28
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 15
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 14
- 125000003545 alkoxy group Chemical group 0.000 abstract description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract description 8
- 125000003118 aryl group Chemical group 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 7
- 150000003839 salts Chemical class 0.000 abstract description 7
- 125000005163 aryl sulfanyl group Chemical group 0.000 abstract description 6
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract description 6
- 125000005171 cycloalkylsulfanyl group Chemical group 0.000 abstract description 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract description 5
- 125000004414 alkyl thio group Chemical group 0.000 abstract description 5
- 125000004104 aryloxy group Chemical group 0.000 abstract description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract description 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 description 31
- 125000005843 halogen group Chemical group 0.000 description 29
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 28
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 17
- 229930192474 thiophene Natural products 0.000 description 14
- 229910003827 NRaRb Inorganic materials 0.000 description 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 13
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 10
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 6
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000004442 acylamino group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 4
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 4
- 150000003852 triazoles Chemical class 0.000 description 4
- 229910006074 SO2NH2 Inorganic materials 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 102000012085 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021133 Hypoventilation Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 description 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- BRMDATNYMUMZLN-UHFFFAOYSA-N Piloty's Acid Chemical compound ONS(=O)(=O)C1=CC=CC=C1 BRMDATNYMUMZLN-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000008253 Systolic Heart Failure Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26369809P | 2009-11-23 | 2009-11-23 | |
| US263698P | 2009-11-23 | ||
| US26412909P | 2009-11-24 | 2009-11-24 | |
| US264129P | 2009-11-24 | ||
| PCT/US2010/057844 WO2011063400A1 (en) | 2009-11-23 | 2010-11-23 | Nitroxyl donors for the treatment of pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2611852T3 true ES2611852T3 (es) | 2017-05-10 |
Family
ID=43513876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10784416.9T Active ES2611852T3 (es) | 2009-11-23 | 2010-11-23 | Donadores de nitroxilo para el tratamiento de la hipertensión pulmonar |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20110160200A1 (https=) |
| EP (1) | EP2504003B1 (https=) |
| JP (2) | JP2013511556A (https=) |
| CY (1) | CY1118603T1 (https=) |
| DK (1) | DK2504003T3 (https=) |
| ES (1) | ES2611852T3 (https=) |
| HR (1) | HRP20170183T1 (https=) |
| HU (1) | HUE032253T2 (https=) |
| LT (1) | LT2504003T (https=) |
| PL (1) | PL2504003T3 (https=) |
| PT (1) | PT2504003T (https=) |
| RS (1) | RS55697B1 (https=) |
| SI (1) | SI2504003T1 (https=) |
| SM (2) | SMT201700090T1 (https=) |
| WO (2) | WO2011063339A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011071947A2 (en) | 2009-12-07 | 2011-06-16 | Johns Hopkins University | Bis-acylated hydroxylamine derivatives |
| US20110144067A1 (en) * | 2009-12-07 | 2011-06-16 | Toscano John P | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives |
| AU2013201929B2 (en) | 2011-10-17 | 2015-07-23 | The Johns Hopkins University | N-substituted hydroxylamine derivatives with carbon-based leaving groups |
| HRP20180121T1 (hr) * | 2013-01-18 | 2018-02-23 | Cardioxyl Pharmaceuticals Inc. | Donori nitroksila s poboljšanim terapijskim indeksom |
| CA2912313A1 (en) | 2013-05-14 | 2014-11-20 | Active Biotech Ab | N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors |
| EP3126329B1 (en) | 2014-01-17 | 2019-05-29 | Cardioxyl Pharmaceuticals Inc. | N-hydroxymethanesulfonamide nitroxyl donors |
| EP3148972B1 (en) | 2014-05-27 | 2019-08-21 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| US9464061B2 (en) | 2014-05-27 | 2016-10-11 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives |
| US10730828B2 (en) | 2015-10-19 | 2020-08-04 | Cardioxyl Pharmaceuticals, Inc. | N-hydroxylsulfonamide derivatives as nitroxyl donors |
| KR20180063326A (ko) | 2015-10-19 | 2018-06-11 | 카르디옥실 파마슈티칼스 인코포레이티드 | 니트록실 공여자로서의 피라졸론 유도체 |
| US10913728B2 (en) | 2016-07-28 | 2021-02-09 | The Johns Hopkins University | O-substituted hydroxamic acids |
| US11083704B2 (en) | 2017-01-03 | 2021-08-10 | Bristol-Myers Squibb Company | Method of administering nitroxyl donating compounds |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219428A (en) * | 1961-04-17 | 1965-11-23 | Hooker Chemical Corp | O,n-diacylated-3,4-dihalophenylhydroxylamines as herbicides |
| US3382243A (en) * | 1965-05-17 | 1968-05-07 | American Home Prod | Acetamides and their preparation |
| US3948967A (en) * | 1968-01-03 | 1976-04-06 | Velsicol Chemical Corporation | Aryl urea carbonates |
| US3661944A (en) * | 1970-07-01 | 1972-05-09 | Smith Kline French Lab | 4-(n-lower alkanoyl)hydroxylamino-4'-aminodiphenylsulfone compounds |
| US3746727A (en) * | 1971-06-07 | 1973-07-17 | Shell Oil Co | Benzenesulfhydroxamic acids and their derivatives |
| US3751255A (en) * | 1972-03-24 | 1973-08-07 | Eastman Kodak Co | Photosensitive and thermosensitive element, composition and process |
| JPS567710A (en) * | 1979-06-28 | 1981-01-27 | Sansho Seiyaku Kk | Whitening cosmetic |
| US4405357A (en) * | 1980-06-02 | 1983-09-20 | Fmc Corporation | Herbicidal 3-isoxazolidinones and hydroxamic acids |
| US4539321A (en) * | 1981-10-26 | 1985-09-03 | William H. Rorer, Inc. | 5-Diaza-aryl-3-substituted pyridone compounds |
| DE3583799D1 (de) * | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| US4663351A (en) * | 1985-08-23 | 1987-05-05 | Berlex Laboratories, Inc. | Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent |
| US4798824A (en) * | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
| US5721365A (en) * | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
| US5039705A (en) * | 1989-09-15 | 1991-08-13 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
| US5212204A (en) * | 1989-10-18 | 1993-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Antihypertensive compositions and use thereof |
| JP2773959B2 (ja) * | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| EP0604525A1 (en) * | 1991-09-20 | 1994-07-06 | Zeneca Limited | Enzymatic production of optical isomers of tetrahydropyran-2-ones |
| AU668107B2 (en) * | 1991-09-24 | 1996-04-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| US5814666A (en) * | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5278192A (en) * | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
| US6200558B1 (en) * | 1993-09-14 | 2001-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| EP0703902B1 (en) * | 1993-06-24 | 1998-12-16 | Albany Molecular Research, Inc. | Process for the production of piperidine derivatives |
| ATE192922T1 (de) * | 1993-11-02 | 2000-06-15 | Us Health | Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden |
| US5700830A (en) * | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
| US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US6043232A (en) * | 1997-07-23 | 2000-03-28 | Nitromed, Inc. | Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs |
| US5674894A (en) * | 1995-05-15 | 1997-10-07 | G.D. Searle & Co. | Amidine derivatives useful as platelet aggregation inhibitors and vasodilators |
| US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| DE19545878A1 (de) * | 1995-12-08 | 1997-06-12 | Basf Ag | Pyridylcarbamate, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung |
| US5824669A (en) * | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| US5958427A (en) * | 1996-11-08 | 1999-09-28 | Salzman; Andrew L. | Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications |
| TW453999B (en) * | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| KR20010031319A (ko) * | 1997-10-24 | 2001-04-16 | 요시히코 시오노 | 항류마티스제 |
| US6596705B1 (en) * | 1998-02-09 | 2003-07-22 | The Regents Of The University Of California | Inhibition of L-selectin and P-selection mediated binding using heparin |
| UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| DE69924735T2 (de) * | 1998-07-28 | 2006-01-19 | Tanabe Seiyaku Co., Ltd. | Zur wirkstoffabgabe an zielorten im darm fähige zubereitung |
| EP1126838A4 (en) * | 1998-10-30 | 2005-02-16 | Nitromed Inc | NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| PL353199A1 (en) * | 1999-08-30 | 2003-11-03 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| US7045152B2 (en) * | 1999-09-08 | 2006-05-16 | Duke University | Treating pulmonary disorders with gaseous agent causing repletion of GSNO |
| US20010053795A1 (en) * | 2000-06-20 | 2001-12-20 | Bond Richard A. | Paradoxical pharmacology |
| CA2410632A1 (en) * | 2000-06-22 | 2001-12-27 | David S. Garvey | Nitrosated and nitrosylated taxanes, compositions and methods of use |
| JP4092203B2 (ja) * | 2000-12-21 | 2008-05-28 | ニトロメッド，インク． | 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法 |
| WO2003006427A1 (en) * | 2001-07-12 | 2003-01-23 | Johns Hopkins University | Compounds that release nitric oxide at controlled rates upon photolysis |
| FR2832634A1 (fr) * | 2001-11-29 | 2003-05-30 | Univ Pasteur | Utilisation des isomeres l de derives aminoacides de l'hydroxyguanidine pour la production de no, compositions pharmaceutiques les contenant et utilisations pharmaceutiques |
| US20040038947A1 (en) * | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
| US20040077691A1 (en) * | 2002-06-21 | 2004-04-22 | Medinox, Inc. | Hydroxamate derivatives of non-steroidal anti-inflammatory drugs |
| US6936639B2 (en) * | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
| US20050009789A1 (en) * | 2003-05-13 | 2005-01-13 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service | Cyclooxygenase inhibition with nitroxyl |
| WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| CA2554771A1 (en) * | 2004-01-30 | 2005-08-18 | Johns Hopkins University | Nitroxyl progenitor compounds and methods of use |
| EP1846439A2 (en) * | 2005-01-31 | 2007-10-24 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
| EP1909779A1 (en) * | 2005-06-23 | 2008-04-16 | Johns Hopkins University | Thiol-sensitive positive inotropes |
| US20070088043A1 (en) * | 2005-10-18 | 2007-04-19 | Orchid Research Laboratories Limited. | Novel HDAC inhibitors |
| BRPI0708804B8 (pt) * | 2006-03-17 | 2021-05-25 | Cardioxyl Pharmaceuticals Inc | compostos derivados de n-hidroxilsulfonamida como doadores de nitroxil, composição farmacêutica e kit |
| NZ584036A (en) * | 2007-09-26 | 2012-06-29 | Univ Johns Hopkins | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| LT2278975T (lt) * | 2008-05-07 | 2016-11-25 | Cardioxyl Pharmaceuticals Inc. | Nauji nitrozo junginiai kaip nitroksilo donorai, ir jų panaudojimo būdas |
| WO2011071947A2 (en) * | 2009-12-07 | 2011-06-16 | Johns Hopkins University | Bis-acylated hydroxylamine derivatives |
| US20110144067A1 (en) * | 2009-12-07 | 2011-06-16 | Toscano John P | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives |
-
2010
- 2010-11-22 WO PCT/US2010/057640 patent/WO2011063339A1/en not_active Ceased
- 2010-11-22 US US12/951,900 patent/US20110160200A1/en not_active Abandoned
- 2010-11-23 HR HRP20170183TT patent/HRP20170183T1/hr unknown
- 2010-11-23 HU HUE10784416A patent/HUE032253T2/en unknown
- 2010-11-23 WO PCT/US2010/057844 patent/WO2011063400A1/en not_active Ceased
- 2010-11-23 PT PT107844169T patent/PT2504003T/pt unknown
- 2010-11-23 LT LTEP10784416.9T patent/LT2504003T/lt unknown
- 2010-11-23 ES ES10784416.9T patent/ES2611852T3/es active Active
- 2010-11-23 PL PL10784416T patent/PL2504003T3/pl unknown
- 2010-11-23 SI SI201031332A patent/SI2504003T1/sl unknown
- 2010-11-23 JP JP2012540154A patent/JP2013511556A/ja active Pending
- 2010-11-23 SM SM20170090T patent/SMT201700090T1/it unknown
- 2010-11-23 DK DK10784416.9T patent/DK2504003T3/en active
- 2010-11-23 RS RS20170138A patent/RS55697B1/sr unknown
- 2010-11-23 EP EP10784416.9A patent/EP2504003B1/en active Active
-
2015
- 2015-04-24 US US14/696,319 patent/US20160081951A1/en not_active Abandoned
-
2016
- 2016-01-29 JP JP2016015102A patent/JP2016128481A/ja active Pending
-
2017
- 2017-02-07 CY CY20171100169T patent/CY1118603T1/el unknown
- 2017-02-09 SM SM201700090T patent/SMT201700090B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE032253T2 (en) | 2017-09-28 |
| WO2011063339A1 (en) | 2011-05-26 |
| LT2504003T (lt) | 2017-01-25 |
| JP2013511556A (ja) | 2013-04-04 |
| US20160081951A1 (en) | 2016-03-24 |
| US20110160200A1 (en) | 2011-06-30 |
| SMT201700090T1 (it) | 2017-03-08 |
| PT2504003T (pt) | 2017-01-31 |
| WO2011063400A1 (en) | 2011-05-26 |
| HRP20170183T1 (hr) | 2017-03-24 |
| RS55697B1 (sr) | 2017-07-31 |
| DK2504003T3 (en) | 2017-02-20 |
| EP2504003B1 (en) | 2016-11-09 |
| JP2016128481A (ja) | 2016-07-14 |
| CY1118603T1 (el) | 2017-07-12 |
| EP2504003A1 (en) | 2012-10-03 |
| SMT201700090B (it) | 2017-03-08 |
| SI2504003T1 (sl) | 2017-01-31 |
| PL2504003T3 (pl) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2611852T3 (es) | Donadores de nitroxilo para el tratamiento de la hipertensión pulmonar | |
| Gómez et al. | Effects of nebulized NG‐nitro‐L‐arginine methyl ester in patients with hepatopulmonary syndrome | |
| Barber et al. | Oxygen toxicity in man: a prospective study in patients with irreversible brain damage | |
| BR112020012586A2 (pt) | composições e métodos de tratamento para transtornos neurológicos que contenham uma forma de demência | |
| WO2020131998A1 (en) | Notch inhibitors for the treatment of vascular malformations | |
| BR112017024854B1 (pt) | Uso de um composto | |
| ES2616470T3 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| AU2016270874A1 (en) | Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry | |
| JP5693224B2 (ja) | 方法及び該方法で使用するためのイメージング媒体 | |
| ES2965890T3 (es) | Acilsulfonamidas que son antagonistas de la familia Bcl para su uso en la gestión clínica de afecciones provocadas o mediadas por células senescentes y para tratar cáncer | |
| TW201834637A (zh) | 緩釋型組成物、其製備方法及其用途 | |
| ES2830759T3 (es) | Moduladores de ROR-GAMMA (RORY) | |
| WO2011071088A1 (ja) | スーパーオキシド製造方法、スーパーオキシド消去能評価方法、スーパーオキシド製造装置およびスーパーオキシド消去能評価装置 | |
| RU2208454C2 (ru) | Препараты для медицинского применения, обеспечивающие возможность диагностики с использованием ядерного магнитного резонанса, с помощью скалярного взаимодействия | |
| ES2941628T3 (es) | Método de tratamiento de la fibrosis pulmonar idiopática | |
| ES2951306T3 (es) | Utilización de compuesto en la preparación de fármaco para tratar la enfermedad de los vasos cerebrales pequeños | |
| Blacklow et al. | Organ culture of human aorta: prolonged survival with support of viral replication | |
| TW201033225A (en) | Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same | |
| Burrage et al. | Effects of histamine and epinephrine on the small pulmonary blood vessels of living rabbits | |
| Vinokurov et al. | Cytoprotective action of sodium fumarate in an in vitro model of hypoxia using sodium dithionite | |
| Razumovskiy et al. | Modern approaches to the surgical treatment of biliary atresia | |
| TW201625238A (zh) | 抗血小板劑及其用途 | |
| Berger et al. | Absence of residual tumor tissue after Gamma Knife radiosurgery followed by resection of a vestibular schwannoma: illustrative case | |
| ES3028375T3 (en) | 1,2-dihydroquinoline-2-ones for their use in the treatment of limb-girdle muscular dystrophy | |
| CN114159445B (zh) | 筛选抑制新型冠状病毒感染的小分子药物的方法及其应用 |